Key Highlights
- Shares are trading down 9.02% to $275.80, hitting a new 52-week low.
- CFO Preston Wells disclosed at the Wells Fargo Healthcare Conference that a Manufacturing issue hampering the peripheral vascular Business will persist through the third quarter and partly into the fourth quarter.
- The company's hoped-for recovery in its orthopedics and joint replacement business has yet to materialize.
- The warning overshadowed an otherwise strong second-quarter beat, with EPS of $3.69 versus a $3.49 estimate and Revenue up 9.4% year over year to $6.59 billion.
- Rival Zimmer Biomet (NYSE:ZBH) also slid on the read-through, while analysts largely maintained Moderate Buy ratings with an average price target near $386.
Shares Hit a New Low on a Manufacturing Delay Warning
A NYSE-listed medical device company is trading sharply lower today, hitting a new 52-week low, despite having beaten Earnings estimates in its most recent quarter, a reaction that runs counter to what would typically be viewed as positive news. Stryker (NYSE:SYK), speaking through CFO Preston Wells at the Wells Fargo Healthcare Conference, disclosed that a manufacturing issue hampering its peripheral vascular business will persist through the third quarter and partly into the fourth quarter, longer than previously guided.
Orthopedics Recovery Has Yet to Materialize
The company also disclosed that its hoped-for recovery in the orthopedics and joint replacement business has yet to materialize, adding to investor concern about near-term revenue mix. Stryker operates through its Orthopaedics and Spine segment, providing implants for joint replacement, and its MedSurg and Neurotechnology segment, which includes its Mako robotics platform.
Warning Overshadows a Strong Earnings Beat
The stark warning overshadowed an otherwise strong second-quarter beat, with Earnings Per Share of $3.69 versus a $3.49 estimate and revenue up 9.4% year over year to $6.59 billion. The disconnect between the solid quarterly results and today's guidance-driven warning appears to be spooking investors about the company's near-term revenue trajectory more than its recent performance.
Sector Read-Through and Analyst Reaction
Rival Zimmer Biomet (NYSE:ZBH) also slid on the read-through from Stryker's disclosure, while analysts largely maintained Moderate Buy ratings with an average price target near $386, though some have trimmed targets. The selloff has drawn some value-oriented commentary suggesting a better entry point despite the deteriorating near-term outlook, with continued clarity on the peripheral vascular manufacturing timeline likely to be the key catalyst for the stock ahead.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...